Increased Diversity in Clinical Trials
Two of our two networks—LatinosAgainstAlzheimer’s and AfricanAmericansAgainstAlzheimer’s—are increasing awareness and clinical trial participation among these communities that are typically underrepresented in research.
See: Forget Me Not—a play presented by AfricanAmericansAgainstAlzheimer’s.
Listen: Alzheimer’s Talks—a discussion of the motivations and barriers of participation among diverse communities.
This call was hosted by Jason Resendez, Executive Director of LatinosAgainstAlzheimer’s, and Dr. Goldie Byrd, Director of the Center for Outreach in Alzheimer’s Aging and Community Health at North Carolina A&T State University. They were joined by Daisy Duarte and Valerie Smith, both of whom have volunteered for clinical trials and are also caregivers for loved ones with Alzheimer’s or memory loss.
Watch: Five Ways to Improve Minority Participation in Clinical Trials—a panel including Jason Resendez, Executive Director of LatinosAgainstAlzheimer’s.
Speeding the Clinical Trial Process
Global Alzheimer’s Platform (GAP)
Part of the UsAgainstAlzheimer’s enterprise, the GAP Foundation is joining together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to establish a standing global trial-ready platform to drive quality, efficiency, and innovation in Alzheimer’s clinical trials. GAP seeks to reduce the length of clinical trials by up to two years by building a network of certified high-performance clinical trial sites committed to standardizing processes and performance measurements.
Single Endpoint for New Drug Approvals for Alzheimer’s Disease
Read Report: Single Endpoint for New Drug Approvals for Alzheimer’s Disease.
Read Press Release: Alzheimer’s Experts Call for Changes in FDA Drug Approval Standards to Stimulate Research and Development.
Listen: Alzheimer’s Talks with Dr. Howard Fillit, Founding Executive Director and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation and a Founding Member of ResearchersAgainstAlzheimer’s.
Listen: Alzheimer’s Talks: Improving the Pace and Quality of Clinical Trials with Dr. Laurie Ryan, Chief of the Dementias of Aging Branch in the Division of Neuroscience at the National Institute on Aging.
Drive New Research and Discoveries
A-LIST: An online community partnering with researchers for an Alzheimer’s cure. A-LIST members take surveys on what matters most to them to help researchers focus their work on the symptoms and issues that of most importance. The A-LIST supports AD-PACE, a patient-focused drug development initiative of UsAgainstAlzheimer’s.
Alzheimer's Disease Education and Referral Center (ADEAR): A tool to find Alzheimer’s disease clinical trials run by the National Institute on Aging at NIH.
ASSIST Study: The Alzheimer’s Disease Discovery Study (ASSIST) Study will digitally collect cognitive data, health history and lifestyle tracking data from at least 400,000 individuals, with an emphasis on diversity.
Memory Strings Community: Connects people to Alzheimer’s research opportunities and helps more than 50 leading research institutions with their clinical trial recruiting efforts. Memory Strings is powered by the Global Alzheimer’s Platform Foundation, an initiative of UsAgainstAlzheimer’s.
Alzheimer's Prevention Registry (APR): Created by Banner Alzheimer’s Institute, this initiative seeks to provide information on the latest research news and support enrollment in studies across the country.
Listen: Alzheimer’s Talks with Dr. Eric Reiman, Executive Director of Banner, about APR and its prevention initiatives.
Healthy Brains: An interactive platform by the Cleveland Clinic to get a brain check-up, track progress and learn more about brain health. The registry will also is a recruitment tool for clinical trials.
Brain Health Registry: An online initiative to reduce the time and costs of clinical trials. Anyone age 18 or older may sign up to answer a short questionnaire and take online neuropsychological tests (brain games). Memory decline can happen over many years, so researchers hope to identify subtle declines that will help find appropriate participants for clinical trials.
Listen: Alzheimer’s Talks with Dr. Michael Weiner, Founder of the Brain Health Registry.
